Search

Displaying results 3321 - 3330 of 7479 in total
  1. Drug

    VPM1002

    go.drugbank.com/drugs/DB15801
    Investigational

    The ability for mycobacterial antigens to reach the cytosol is due to this vaccine being engineered to secrete Hly which perforates phagosomal membranes. … By reducing urease C, phagosome acidification can occur, promoting phagolysosome fusion while also providing the optimal low pH for listeriolysin O stability.

  2. Drug

    rsPSMA Vaccine

    go.drugbank.com/drugs/DB06361
    ApprovedWithdrawn

    Prostate-specific membrane antigen (PSMA) is an ∼100 kDa transmembrane glycoprotein that is abundantly and preferentially expressed in prostate cancer, including recurrent and hormone-refractory cases.

  3. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    [L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.

  4. Drug

    Human papillomavirus type 31 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10310
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 31.

  5. Drug

    Egaptivon pegol

    go.drugbank.com/drugs/DB05202
    Investigational

    Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. Egaptivon pegol is being investigated for the treatmen...

  6. Drug

    Fluoride ion

    go.drugbank.com/drugs/DB11257
    ApprovedInvestigational

    It also plays an essential physiological role, such as enhancing the resistance profile and strength of the surface tooth enamel.

    Mixtures: ZYMAFLUOR D 500, ZYMAFLUOR D 500
  7. Drug

    Midostaurin

    go.drugbank.com/drugs/DB06595
    ApprovedInvestigational

    It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.

  8. Drug

    Human papillomavirus type 52 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10313
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 52 The vaccine is prepared from the purified virus-like particles

  9. Drug

    Mirdametinib

    go.drugbank.com/drugs/DB07101
    ApprovedInvestigational

    [L52485] NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the _NF1_ tumour suppressor gene,[A265065,A265070] leading to neurofibromin dysfunction and aberrant activation

  10. Drug

    Cocaine

    go.drugbank.com/drugs/DB00907
    ApprovedIllicitInvestigational

    An alkaloid ester extracted from the leaves of plants including coca.